Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Rosmarin

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
The British Journal of Dermatology|February 26, 2019
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativaL Prussick, B Rothstein, D Joshipura, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
The British Journal of Dermatology|February 26, 2019
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativaL Prussick, B Rothstein, D Joshipura, et al.
The British Journal of Dermatology|February 6, 2019
Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trialsA Blauvelt, D Rosmarin, T Bieber, et al.
Pageof 2